Comparison of Immune Responses Elicited by Ad5F35-AEgp145 Alone or in Combination with rMVA-AEgp145
Viruses · 2026
DOI: 10.3390/v18010079 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2026. Verfasst von Jing Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention,…. Hauptthemen laut MEDLINE: AIDS Vaccines, Vaccinia virus, HIV-1, Adenoviridae. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capacity building-Research on monitoring and predictive early warning technology of un-known and emerging pathogens, the National Science and Technology Major Project, Capacity building-Research.
Abstract (Originalsprache)
Background
Developing an effective vaccine is crucial for the prevention and control of AIDS. Viral vector-based vaccines, particularly those utilizing homologous or heterologous prime-boost strategies, represent an important direction in current HIV vaccine research.
Methods
In this study, replication-defective chimeric adenovirus Ad5F35 and modified vaccinia virus Ankara (rMVA) vector vaccines expressing the HIV-1 AEgp145 were successfully constructed, designated as Ad5F35-AEgp145 and rMVA-AEgp145, respectively. Sixty BALB/c mice were randomly divided into three groups: Ad5F35 alone, rMVA prime/Ad5F35 boost, and PBS control. The mice were immunized intramuscularly at weeks 0 and 3, and humoral and cellular immune responses were assessed at 4, 8, 12, and 16 weeks after the initial immunization.
Results
The homologous Ad5F35 and heterologous rMVA/Ad5F35 vaccination regimens elicited comparable levels of HIV Env-specific cellular immune responses, peaking at 2100 ± 222 SFCs/million splenocytes and 2200 ± 619 SFCs/million splenocytes, respectively (p > 0.05). Compared to the heterologous regimen, the homologous Ad5F35 regimen induced significantly higher levels of gp120-binding antibodies at weeks 4 and 8 post-initial immunization, with geometric mean titers of 1:25,600 ± 7011 versus 1:1280 ± 150.7 and 1:10,240 ± 4048 versus 1:2560 ± 391.9, respectively. Furthermore, neutralizing activity at week 8 was significantly higher in the homologous group, with a 50% neutralization titers of 1:45 compared to 1:12 in the heterologous group (p < 0.01).
Conclusion
This study demonstrates that the Ad5F35-AEgp145 vaccine, whether administered alone or in combination with rMVA-AEgp145, effectively induces strong and comparable cellular immune responses targeting HIV-1 Env in mice. While both regimens are effective, homologous immunization elicits moderately higher levels of antibody responses. These findings provide an important foundation for the further investigation of vector-based HIV vaccine formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, Ch…
ORCID-Profile: Xiaozhou He, Yanzhe Hao
Förderung
- Capacity building-Research on monitoring and predictive early warning technology of un-known and emerging pathogens
- the National Science and Technology Major Project
- Capacity building-Research
- National Science and Technology Major Project
Zitieren
APA
Yang, J., Ma, Q., He, X., Li, H., Zhang, X., Hao, Y., & Feng, X. (2026). Comparison of Immune Responses Elicited by Ad5F35-AEgp145 Alone or in Combination with rMVA-AEgp145. Viruses. https://doi.org/10.3390/v18010079
Vancouver
Yang J, Ma Q, He X, Li H, Zhang X, Hao Y, et al. Comparison of Immune Responses Elicited by Ad5F35-AEgp145 Alone or in Combination with rMVA-AEgp145. Viruses. 2026. doi:10.3390/v18010079
BibTeX
@article{Yang2026,
author = {Yang, Jing and Ma, Qi and He, Xiaozhou and Li, Hongxia and Zhang, Xiaoguang and Hao, Yanzhe and Feng, Xia},
title = {Comparison of Immune Responses Elicited by Ad5F35-AEgp145 Alone or in Combination with rMVA-AEgp145},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18010079}
}
EUVIMED